{
    "eid": "2-s2.0-85109660908",
    "title": "Circulating BAFF and CXCL10 levels predict response to pegylated interferon in patients with hbeag-positive chronic hepatitis B",
    "cover-date": "2021-06-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Medicine (all)",
            "@code": "2700",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "APRIL",
        "B cells",
        "BAFF",
        "CXCL10",
        "HBsAg",
        "Hepatitis B",
        "IP-10",
        "Peginterferon"
    ],
    "authors": [
        "Apichaya Khlaiphuengsin",
        "Natthaya Chuaypen",
        "Nattiya Hirankarn",
        "Anchalee Avihingsanon",
        "Megan Crane",
        "Sharon R. Lewin",
        "Pisit Tangkijvanich"
    ],
    "citedby-count": 5,
    "ref-count": 31,
    "ref-list": [
        "Hepatitis B virus infection",
        "Interferon Treatment for Hepatitis B",
        "Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection",
        "Adaptive immunity in HBV infection",
        "Frontiers in B-cell immunology",
        "Functional and clinical aspects of the B-cell-activating factor (BAFF): a narrative review",
        "Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases",
        "Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus",
        "B lymphocyte stimulator protein-associated increase in circulating autoantibody levels may require CD4+ T cells: lessons from HIV-infected patients",
        "B cell activating factor (BAFF) in the natural history of chronic hepatitis C virus liver disease and mixed cryoglobulinaemia",
        "Hepatitis C virus-associated B-cell proliferation--the role of serum B lymphocyte stimulator (BLyS/BAFF)",
        "Serum levels of B-cell activating factor in chronic hepatitis B virus infection: association with clinical diseases",
        "ImPortance of IP-10 in hepatitis B",
        "A case-control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma",
        "Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure",
        "The role of quantitative hepatitis B surface antigen revisited",
        "Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection",
        "Let it B in viral hepatitis?",
        "Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients",
        "Hepatitis B Virus e Antigen Regulates Monocyte Function and Promotes B Lymphocyte Activation",
        "Hepatitis B virus protein X-induced expression of the CXC chemokine IP-10 is mediated through activation of NF-kappaB and increases migration of leukocytes",
        "Expression of IFN-inducible protein-10 in chronic hepatitis",
        "Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes",
        "Predictive Value of Serum IFN-gamma inducible Protein-10 and IFN-gamma/IL-4 Ratio for Liver Fibrosis Progression in CHB Patients",
        "Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B",
        "Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients",
        "Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues",
        "Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy",
        "Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir",
        "Rapid downregulation of programmed death-1 and interferon-gamma-inducible protein-10 expression is associated with favourable outcome during antiviral treatment of chronic hepatitis B",
        "Expression of CXC chemokine IP-10 in patients with chronic hepatitis B"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Melbourne",
            "@id": "60026553",
            "affilname": "University of Melbourne",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026553",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60016965",
            "affilname": "The HIV Netherlands Australia Thailand Research Collaboration",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "National Research University",
        "Chulalongkorn University"
    ]
}